Published in J Carcinog on January 01, 2008
Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol (2009) 3.55
An overview of the c-MET signaling pathway. Ther Adv Med Oncol (2011) 1.95
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol (2012) 1.77
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res (2010) 1.50
MET as a possible target for non-small-cell lung cancer. J Clin Oncol (2013) 1.25
A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol (2014) 1.24
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer (2010) 1.14
Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res (2011) 1.13
The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol (2011) 1.11
Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg (2011) 1.09
Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology (2010) 1.09
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One (2013) 1.03
Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol (2009) 1.00
Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget (2014) 0.98
Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action. Cytotechnology (2012) 0.92
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. PLoS One (2013) 0.91
Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells. J Biol Chem (2013) 0.89
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene (2013) 0.89
Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther (2014) 0.88
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody. J Biol Chem (2015) 0.87
Met interacts with EGFR and Ron in canine osteosarcoma. Vet Comp Oncol (2011) 0.86
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One (2015) 0.85
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol (2016) 0.85
Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med (2010) 0.84
ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling. Oncotarget (2015) 0.84
c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol (2014) 0.83
Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. PLoS One (2015) 0.83
Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results. Isr J Chem (2012) 0.83
Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell Int (2013) 0.83
TGFβ can stimulate the p(38)/β-catenin/PPARγ signaling pathway to promote the EMT, invasion and migration of non-small cell lung cancer (H460 cells). Clin Exp Metastasis (2014) 0.83
Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Exp Mol Med (2013) 0.82
Independent of ErbB1 gene copy number, EGF stimulates migration but is not associated with cell proliferation in non-small cell lung cancer. Cancer Cell Int (2013) 0.82
Pathway analysis for genome-wide association study of lung cancer in Han Chinese population. PLoS One (2013) 0.80
The Potential of panHER Inhibition in Cancer. Front Oncol (2015) 0.80
Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. J Child Adolesc Psychopharmacol (2011) 0.80
Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles. Mol Ther (2015) 0.79
Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR. BMC Complement Altern Med (2014) 0.79
Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. Int J Nanomedicine (2013) 0.78
MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res (2012) 0.78
Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer. Oncotarget (2016) 0.78
Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. World J Gastroenterol (2014) 0.77
MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. J Carcinog (2009) 0.76
Biomarker development in MET-targeted therapy. Oncotarget (2016) 0.76
Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene. Mol Ther (2016) 0.76
Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer. Biochem Biophys Res Commun (2016) 0.76
Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol (2017) 0.75
Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. J Exp Pharmacol (2011) 0.75
MET4 Expression Predicts Poor Prognosis of Gastric Cancers with Helicobacter pylori Infection. Cancer Sci (2016) 0.75
Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells. Cancer Biol Ther (2015) 0.75
Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review. EJNMMI Res (2017) 0.75
Volatile oil from Saussurea lappa exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma. Oncotarget (2016) 0.75
Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer. J Proteome Res (2016) 0.75
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. Oncotarget (2017) 0.75
PKCδ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling. Oncotarget (2016) 0.75
Lysosome trafficking is necessary for EGF-driven invasion and is regulated by p38 MAPK and Na+/H+ exchangers. BMC Cancer (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96
Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem (1987) 5.57
Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem (1997) 4.51
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res (2003) 3.47
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol (1992) 2.53
Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene (2006) 2.49
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem (2000) 2.46
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
The accuracy of EUS-FNA in assessing mediastinal lymphadenopathy and staging patients with NSCLC. Eur Respir J (2005) 2.37
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 2.08
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest (2002) 1.93
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ (1990) 1.62
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res (2007) 1.59
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol (2003) 1.57
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50
HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol (1999) 1.41
Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Invest Ophthalmol Vis Sci (2007) 1.37
Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res (2008) 1.37
Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer (1998) 1.32
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer (2006) 1.29
The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep (1998) 1.26
Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res (2007) 1.22
Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene (1992) 1.16
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther (2007) 1.14
Tyrosine kinase mutations in human cancer. Curr Mol Med (2007) 1.05
The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol (2004) 0.95
Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol (2002) 0.93
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology (2006) 0.90
Role of receptor tyrosine kinases in lung cancer. Methods Mol Med (2003) 0.85
Novel therapies in lung cancer. Hematol Oncol Clin North Am (2005) 0.78
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 2.08
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res (2007) 2.06
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2011) 1.99
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res (2002) 1.84
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J (2012) 1.80
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res (2004) 1.69
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res (2006) 1.64
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res (2007) 1.59
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem (2007) 1.53
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.51
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep (2007) 1.50
Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys (2002) 1.49
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg (2010) 1.46
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem (2001) 1.45
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
Fyn: a novel molecular target in cancer. Cancer (2010) 1.40
Lung carcinoma in African Americans. Nat Clin Pract Oncol (2007) 1.33
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol (2010) 1.31
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol (2008) 1.29
MET as a target for treatment of chest tumors. Lung Cancer (2008) 1.29
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem (2010) 1.27
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
MET as a possible target for non-small-cell lung cancer. J Clin Oncol (2013) 1.25
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One (2010) 1.25
FYN is overexpressed in human prostate cancer. BJU Int (2008) 1.22
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res (2007) 1.19
Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets (2005) 1.16
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev (2008) 1.14
A novel classification of lung cancer into molecular subtypes. PLoS One (2012) 1.13
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol (2010) 1.12
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2002) 1.12
Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg (2012) 1.11
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res (2004) 1.11
The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol (2011) 1.11
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol (2014) 1.09
Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol (2010) 1.08
The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist (2009) 1.07
MET pathway as a therapeutic target. J Thorac Oncol (2009) 1.06
PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res (2010) 1.06
Tyrosine kinase mutations in human cancer. Curr Mol Med (2007) 1.05
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer (2008) 1.05
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res (2011) 1.05
Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology (2012) 1.05
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res (2002) 1.04
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest (2009) 1.04
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem (2002) 1.03
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol (2007) 1.03
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res (2009) 1.03
Targeting c-Kit mutations: basic science to novel therapies. Leuk Res (2004) 1.03
Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther (2011) 1.02
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol (2007) 1.01
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol (2009) 1.01
MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr (2010) 1.00
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res (2011) 0.98
The MET axis as a therapeutic target. Update Cancer Ther (2009) 0.98
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (2013) 0.97
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res (2013) 0.96
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cell Signal (2007) 0.96
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol (2008) 0.95
Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. Cancer Res (2005) 0.95
Generation of comprehensive thoracic oncology database--tool for translational research. J Vis Exp (2011) 0.94
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem (2014) 0.94
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res (2012) 0.93
EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal (2008) 0.93
Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res (2003) 0.92
Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev (2007) 0.92
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther (2008) 0.92
Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity. J Biol Chem (2012) 0.91
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol (2012) 0.91
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J (2011) 0.91
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem (2009) 0.91